|
|
|
Introduction
Every community has its own language, and the HIV community has no exception! If you just tested positive for HIV, you may be bewildered by the dozens of new words you’re hearing for the first time. Don’t worry! The following dictionary defines and explains some of the words people use most often when they’re talking about HIV.
The UK's National Physical Laboratory (NPL) is involved in a collaborative project that is helping to further the understanding of HIV viral protein structure which could lead to new molecular medicines.
Examining different parts of the immune system, OU Health Sciences Center and Washington University in St. Louis researchers are creating a new vaccine using a protein instead of creating antibodies.
The AIDS virus damages the immune system differently than scientists have thought until now, a study on a bacterial infection indicates.
The good news is we’re living longer with HIV. The bad news is we’re aging faster than those not infected HIV. The body’s hyperactive response to the virus, even among those being successfully treated with antiretrovirals, is being eyed as the culprit. Fortunately, researchers already have potential anti-aging and anti-inflammatory treatments in sight.
San Francisco public health doctors are urging patients to begin taking HIV medications soon after their diagnosis rather than waiting until their immune systems become compromised, The New York Times reports. The city’s Department of Public Health will announce the new testing guidelines this week.
The risk of transmitting HIV is significantly reduced in people on successful antiretroviral therapy for more than six months, according to Danish investigators and reported on by aidsmap. The Danish study is published in the online edition of the journal HIV Medicine.
The introduction of rapid tests for HIV and hepatitis is an extremely important development not only from the point of view of streamlining the medical tests and saving time, but from the psychological trauma of the stress of waiting
for the result.
In the three decades since HIV was officially recognized, much progress has been made in developing drugs that allow HIV-positive patients to live longer and healthier lives. Some people have such a low viral count in their bodies that the virus appears to be nearly gone. But if they stop taking HIV medications, the virus will rapidly reappear and reproduce. New evidence may help explain where the virus is hiding and why it is able to replicate so quickly
London, Mar 29 : Providing antibiotics to some newly diagnosed HIV patients could save tens of thousands of patients, but researchers are missing this opportunity, say researchers.
SMYRNA, Ga., March 30 /March 30, 2010l/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA (US Food and Drug Administration) to begin a phase 1 clinical trial for GeoVax's therapeutic vaccine, which is intended as a treatment for individuals infected with HIV (Human Immunodeficiency Virus). The company will begin a non-blinded study in HIV infected individuals who started drug treatment during their first year of infection.
Scientists from the California Institute of Technology (Caltech) have uncovered the structure of key protein in common HIV subgroup.
"Gilead Sciences Inc. may learn this year whether its drugs for treating HIV can also stop people from catching the virus in the first place," Bloomberg writes in a piece that examines the potential benefits and drawbacks to using low-doses of HIV/AIDS medications to reduce a person's risk of becoming infected with HIV. According to the news service, the initial results of 10 trials including more than 20,000 people could be available as early as July.
THURSDAY, April 1 (HealthDay News) -- Four anti-HIV drugs inhibit a retrovirus recently linked to prostate cancer and chronic fatigue syndrome (CFS), say U.S. researchers.
A novel stem cell therapy that arms the immune system with an intrinsic defence against HIV could be a powerful strategy to tackle the disease
NAIROBI, 15 December 2009 (PLUSNEWS) - The executive board of UNITAID, the international health financing agency, has approved the establishment of a patent pool for HIV/AIDS medication, a decision AIDS activists say will go a long way in helping poor nations achieve universal access to treatment.
NAIROBI, 7 December 2009 (PLUSNEWS) - If universal access to HIV prevention, treatment and care is to be achieved, experts recommend an inclusive approach to healthcare, rather than narrow HIV programmes.
If an HIV vaccine became available tomorrow, would the world line up for it? It depends on the level of protection it affords, says a research team from the University of California at Los Angeles.
A new vaccine called mycobacterium vaccae (MV) might prevent tuberculosis (TB) in HIV-positive people, according to a new study published in the journal AIDS and reported on by HealthDay News. TB is the most common cause of death among HIV-positive people indeveloping countries.
Researchers found a new antiviral drug that appears to effectively target not only HIV, but also Ebola, influenza and Rift Valley fever, according to a study published online January 28 in the Proceedings of the National Academy of Sciences.
People with HIV can achieve just as much benefit from treatment in “real world” clinics as they do in clinical trials, according to a University of Alabama at Birmingham (UAB) study published February 15 in Clinical Infectious Diseases and reported by aidsmap.
Writing as the co-founder of the Bill & Melinda Gates Foundation, Bill Gates discussed HIV/AIDS in his annual letter. The Microsoft billionaire-turned-philanthropist stressed the importance of scaling up prevention efforts such as male circumcision, ensuring access to care in developing countries and supporting vaccine research.
A research team from the University of Missouri at Columbia is developing a novel nucleoside reverse transcriptase inhibitor (NRTI) that remains active against HIV for days after a single dose, according to a report published online by ScienceDaily. Stefan Sarafianos, PhD, who heads to the MU team, said the compound is more potent and longer-lasting than current NRTIs and may find use not only as a component of antiretroviral (ARV) therapy but also as a preventive microbicide.
If an HIV vaccine became available tomorrow, would the world line up for it? It depends on the level of protection it affords, says a research team from the University of California at Los Angeles.
NAIROBI, 1 February 2010 (PLUSNEWS) - Scientists have finally discovered the structure of a key enzyme found in HIV and similar viruses, abreak through that has crucial implications for HIV treatment.
NAIROBI, 30 November 2009 (PLUSNEWS) - The World Health Organization (WHO) issued a new set of guidelines for the treatment of HIV and prevention of mother-to-child transmission (PMTCT) on 30 November.
JOHANNESBURG, 24 September 2009 (PLUSNEWS) - A six-year clinical trial in Thailand has yielded the first ever evidence that an AIDS vaccine can provide some protection against HIV infection.
An Interview With Jeffrey Laurence, M.D.By Bonnie Goldman
2 September 2009 – Cape Town, Gaborone, Maseru, Manzini – Southern African TB and HIV activists have welcomed the emphasis placed on tackling increasing levels of TB, HIV and malaria drug resistance, at the Africa regional health committee meeting taking place in Rwanda this week; while accentuating that a bigger paradigm shift is needed to ensure a successful response to rising levels of drug resistance in the regional TB-HIV co-epidemic.
JOHANNESBURG, 9 September 2009 (PLUSNEWS) - Many countries struggle to pay for antiretroviral (ARV) drugs for all those who need them, but a new study has found that some nations are paying up to three times more for the life-prolonging medicines than others with similar HIV prevalence and income levels.
NAIROBI, 4 September 2009 (PLUSNEWS) - The search for an AIDS vaccine has taken a step forward with the discovery of two powerful new antibodies that can cripple the HI virus.
NAIROBI, 3 September 2009 (PLUSNEWS) - AIDS activists have praised a decision by the Indian patent office to reject patent applications for two life-prolonging antiretroviral (ARV) drugs, allowing Indian manufacturers to keep on making and exporting generic versions.
NAIROBI, 7 August 2009 (PLUSNEWS) - The Clinton Foundation has announced agreements with two drug companies to bring the cost of second-line antiretrovirals (ARVs) to under US$500 per person annually and reduce the cost of a key tuberculosis (TB) drug to $1 per dose.
JOHANNESBURG, 16 July 2009 (PLUSNEWS) - New research has again confirmed the importance of viral load testing, which measures the amount of HI virus in the blood, to determine whether someone on antiretroviral (ARV) treatment is experiencing treatment failure and needs to be switched to a second-line drug regimen.
This information will help you understand your choices, whether you share in the decision-making process or rely on your doctor's recommendation.
Taking antiretroviral drugs for HIV will not cure your infection. However, it may allow you to remain healthy for a long time.
JOHANNESBURG, 28 July 2009 (PLUSNEWS) - The goal of achieving universal access to treatment by 2010 has preoccupied the global AIDS community in recent years, but a new report warns that not preparing for the changing treatment needs of people living with HIV will doom the sustainability of treatment programmes in developing countries.
CAPE TOWN, 21 July 2009 (PLUSNEWS) - The idea of using antiretroviral drugs (ARVs) not only to treat HIV infection but also to prevent new infections,and eventually to eradicate the virus almost entirely, is being hotly debated at the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa, this week.
In a study published in The Journal of Infectious Diseases, researchers from Albert Einstein College of Medicine of Yeshiva University have identified cells in blood that predict which HIV-positive individuals are most likely to develop deadly fungal meningitis, a major cause of HIV-related death. This form of meningitis affects more than 900,000 HIV-infected people globally—most of them in sub-Saharan Africa and other areas of the world where antiretroviral therapy for HIV is not available.
A new WHO study has revealed that HIV-positive babies who received the BCG vaccine against tuberculosis were three times more likely to contract the infectious disease. Medical experts have raised concerns over the complications among the vaccinated kids.
Researchers have found that HIV-1 virus moves rapidly in the body, and damages the B-cell antibody-producing system in the gut, within days of infection.
programs, UNAIDS, World Bank report says
Scientists at Albert Einstein College of Medicine of Yeshiva University have devised a laboratory test for predicting whether microbicides against HIV are safe for human use. The researchers have also discovered why several supposedly “safe” microbicides made women more susceptible to HIV infection. The study appears today in the online version of the Journal of Infectious Diseases.
People living with HIV have differing needs depending their personal circumstances and stage of infection. Forms of HIV treatment and care can be grouped into three broad categories according to when they are usually first needed. A comprehensive package of care covers the entire journey from diagnosis to death, which with antiretroviral treatment may span several decades.
Forum
FAQ